Market Research Logo
Region: Africa
Category: Country Overviews

Africa Country Overviews

(78 reports matching your criteria)
  • Cameroon Pharmaceuticals & Healthcare Q1 2018

    ... significant underlying burden of infectious diseases, the burden of non-communicable diseases will continue to increase at a faster rate due to the growing middle class and resulting lifestyle changes, providing improved revenue-earning opportunities for drugmakers ... Read More

  • Morocco Pharmaceuticals & Healthcare Q1 2018

    ... disease treatments. The government's commitment to improving healthcare via the expansion of health insurance coverage will be a significant factor for future medicine sales growth; however, generics drugmakers will be the main beneficiaries as the ... Read More

  • Ghana Pharmaceuticals & Healthcare Q1 2018

    ... Ghanaian government. This also makes up part of Ghana's ongoing economic diversification efforts, parallel to investment into infrastructure, mining and industrial development. Despite a stable economic and political outlook, weak regulatory procedures and operational risks ... Read More

  • Mozambique Pharmaceuticals & Healthcare Q1 2018

    ... has the potential to give rise to strong medicine sales growth, the lack of affordability among the population will mean growth will mainly be in the generic drug segment. High levels of corruption and an ... Read More

  • Algeria Pharmaceuticals & Healthcare Q1 2018

    ... forecast period, driven by rising demand for healthcare and a growing prevalence of chronic diseases. Incentives for pharmaceutical investment will continue to boost local manufacturing capacity. Meanwhile, upside risks are mounting towards drug pricing reform, ... Read More

  • Mauritius Pharmaceuticals & Healthcare Q1 2018

    ... drugmakers over the next ten years. Maurit ius's increasing integration with larger African markets will benefit the island nation health industries while expanding export markets for drug manufacturers over the long term. Mauritius's strategic position ... Read More

  • Angola Pharmaceuticals & Healthcare Q1 2018

    ... such as these will have important implications for public healthcare provision and the long-term potential of Angola's pharmaceutical market. However, opportunities for drugmakers will remain weak, with the country expected to see little improvement regarding ... Read More

  • Sudan and South Sudan Pharmaceuticals & Healthcare Q1 2018

    ... market. While the removal of restrictions will improve Sudan's economic growth outlook and relations with the US, the operating environment remains highly challenging and will continue to restrict company activity from foreign drugmakers. Over the ... Read More

  • Egypt Pharmaceuticals & Healthcare Report Q1 2018

    ... the market's trajectory include the country's growing demand for prescription medicines, a rapid increase in the country's population and growing health awareness. Disputes over medicine pricing, the impact of high inflation and the lasting negative ... Read More

  • South Africa Pharmaceuticals & Healthcare Report Q1 2018

    ... looking to develop a foothold in the wider region. Given the size of the market, it is vital that companies appreciate the varying levels of both investment risk and reward that are present at the ... Read More

  • Cote d'Ivoire Pharmaceuticals & Healthcare Report Q1 2018

    ... universal healthcare will drive demand for prescription medicines, with generic drugmakers the likely beneficiaries. While we hold a more positive long-term outlook for Cote d'Ivoire's potential for pharmaceutical investment, significant market access barriers will need ... Read More

  • Middle East And North Africa Pharmaceuticals and Healthcare Report Q4 2017

    ... diversifiedtherapeutic development from firms in the region. Crucially, a country-specific approach is integral forpharmaceutical companies as they must adapt to the evolving pricing landscape, differing levels of patentprotection and the level of competition within each ... Read More

  • Zambia Pharmaceuticals and Healthcare Report Q4 2017

    ... force unemployed, geographical and financial access to medicines forthe majority of the population is largely restricted. Headline Expenditure Forecast Pharmaceuticals: ZMW1.80bn (USD174mn) in 2016 to ZMW1.93bn (USD204mn) in 2017; +7.4% inlocal currency terms and 17.2% ... Read More

  • Sub-Saharan Africa Pharmaceuticals and Healthcare Report Q4 2017

    ... the region, where the rewards are brighter forinnovative drugmakers' portfolios and have longer-term potential. Headline Expenditure Projections Pharmaceuticals: USD12.0bn in 2016 to USD12.3bn in 2017; 3.1% in US dollar terms. Healthcare: USD79.1bn in 2016 to ... Read More

  • Tunisia Pharmaceuticals and Healthcare Report Q4 2017

    ... a notable impact on developments within the pharmaceutical sector and wider economy;however, the actual benefits will take time to materialise. Crucially, higher growth opportunities willpresent themselves within the generic medicines sector, while the high industry-associated ... Read More

  • Ethiopia Pharmaceuticals and Healthcare Report Q4 2017

    ... Ethiopia remains a long way from achieving sustainable medicine production. Greaterinterest from foreign investors and further government support will boost the capacity of Ethiopia'spharmaceutical landscape over the long term; however, opportunities for patented firms will ... Read More

  • Botswana Pharmaceuticals and Healthcare Report Q4 2017

    ... committed to improving healthcare infrastructure in the country and to tackling the nation's high communicable disease burden, particularly HIV/AIDS. However, the country's small market size will dampen multinational interest, with drugmakers choosing South Africa as ... Read More

  • Sudan Pharmaceuticals and Healthcare Report Q4 2017

    ... economy, a combination of high inflation, poor consumer spending and political fragilities will undermine the pace of pharmaceutical market growth. The government's plans to improve domestic pharmaceutical manufacturer capabilities will attempt to reduce ongoing medicine ... Read More

  • Tanzania Pharmaceuticals and Healthcare Report Q4 2017

    ... tabled before the end of the year. A rapidly rising low-income population of over 55 million coupled with a high disease burden will drive demand for low-cost generic medicines. We expect Tanzania's small pharmaceutical sector ... Read More

  • Mauritius Pharmaceuticals and Healthcare Report Q4 2017

    ... well as the rising demand for chronic disease treatment, will underpin market growth. Meanwhile, new tax incentives for drug manufacturers and the government's active support for the sector's development will encourage drug production as well ... Read More

  • Uganda Pharmaceuticals and Healthcare Report Q4 2017

    ... of the country's public health spending suggests a weak outlook for public healthcare sector provision. Strong private consumption growth will drive medicine spending, with opportunities being presented for multinationals selling high-value patented drugs. Headline Expenditure ... Read More

  • Kenya Pharmaceuticals and Healthcare Report Q4 2017

    ... and increasing chronic disease burden. Strict controls of illegal drug dealings will have asignificant impact on drugs sales within the country. Though it does not yet cover the majority of thecountry's population, the innovative measures ... Read More

  • Zimbabwe Pharmaceuticals and Healthcare Report Q4 2017

    ... pharmaceutical firms to invest locally. As such, we expect theZimbabwean government to prioritise the local generic drug industry in order to control costs and boostdomestic drugmaker competitiveness. Besides encouraging greater investment into local drugmanufacturing, the ... Read More

  • Ghana Pharmaceuticals and Healthcare Report Q4 2017

    ... investment is marred by theelevated industry-specific risks. In particular, the country's stable economic and political regime bode wellfor investment over the coming years, yet the small pharmaceutical market size will ensure this is focussedwithin the ... Read More

  • Morocco Pharmaceuticals and Healthcare Report Q4 2017

    ... of healthcare infrastructure inthe country. The acknowledgment of shortcomings regarding healthcare coverage and medicine, along withthe government's plans to address such issues, is reassuring, highlighting that the country remainscommitted to increasing access to medicines and ... Read More

< prev 1 3 4